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of *Anesthesiology and tNeurology, The Mount Sinai Medical Center, New York, New York Dopamine (DA) is released in large quantities from the striatum during cerebral ischemia. Along with excitatory neurotransmitters, DA plays a role in cellular neuronal ischemic injury. In this study we examined the role of nitric oxide (NO) in the ischemia-induced release of DA. A microdialysis probe was stereotactically placed into the corpus striatum of 16 Sprague-Dawley rats for DA, 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) level determinations. After probe stabilization, the animals received either flnitro-L-arginine-methyl ester (L-NAME), a NO synthase inhibitor, or vehicle through the microdialysis probe. Temporary global forebrain ischemia was induced using bilateral carotid artery ligature tightening and controlled hemorrhagic hypotension for 15 min. L-NAME administration caused a reduction in ischemic estimated extraneuronal DA concentration by 60% (P < 0.005) compared with control. There was an increase in both DOPAC and HVA concentrations during the recovery period compared to baseline values in the control group (P < 0.05). L-NAME also caused a reduction in HVA concentration compared to vehicle administration during the latter part of recovery (P < 0.05). These data support the concept that ischemic dopamine release may be mediated by NO. This NO-modulated DA release may contribute to the previously reported deleterious neurotoxic effects of NO during ischemia.
(Anesth Analg 1995;80:1116-21)
T he small-to medium-sized neurons of the dorsolateral corpus striatum are more susceptible to ischemic injury than most other neuronal units (1) . Catecholaminergic nerve terminals are more sensitive to ischemic damage than serotoninergic, GABAergic, or glutaminergic neurons (2,3). Dopamine (DA) is released in large quantities by the corpus striatum during anoxia, hypoglycemia, and ischemia (4-7). Excessive neuronal DA release has been implicated as a major factor in the pathogenesis of neuronal damage to the striatum (8-10). In animals in which DA depletion was induced in the corpus striatum, Weinberger et al. (101 and Globus et al. (11) observed a significant reduction in neuronal damage ischemic insult.
Breakdown products of DA also may be involved in neuronal injury. DA may be converted to homovanillic acid (HVA) through one of two biochemical pathways. In the first pathway, DA is metabolized to 3,4-dihydroxyphenylacetic acid (DOPAC) by monoamine oxidase and subsequently to HVA by catechol 0-methyltransferase.
Alternatively, DA may be converted to 3-methoxytyramine by catechol 0-methyltransferase and subsequently to HVA by monoamine oxidase. During the conversion of DA to DOPAC, hydrogen peroxide, superoxide, and hydroxyl radicals are formed. These byproducts are potentially neurotoxic and may contribute to further neuronal injury during DOPAC synthesis (12).
Nitric oxide (NO), produced endogenously by the conversion of L-arginine to L-citrulline by nitric oxide synthase (NOS), is an important modulator of vascular tone, platelet adhesion, and neurotransmission (13). There is increasing evidence that there is significant NO production during cerebral ischemia, and its release, or modulation of its release, may be an important factor in the pathogenesis of neuronal ischemic injury (14). To date, there have been numerous studies of the effects of NO donors and inhibitors of NOS on histopathologic outcome but with conflicting results (15-21). The difference may be due to the differential effects of NO on cerebral blood flow (CBF) and neurotoxicity during ischemia.
In this study, we examined a possible mechanism of action of NO during cerebral ischemia. In particular, we examined the effect of NOS inhibition on 
Methods
The study protocol was approved by our institution's animal care and use committee. Light-cycled Sprague-Dawley rats (250-325 g) were fasted for 12 h but allowed free access to water prior to the experiment. Anesthesia was induced using intraperitoneal chloral hydrate, 400 mg/kg, and maintained with supplemental chloral hydrate intraperitoneally, 100 mg/kg. All surgical sites were infiltrated with bupivacaine 0.25%. A femoral vein and artery were cannulated for drug infusion, pressure monitoring, and blood withdrawal. Both carotid arteries were dissected from the vagus nerve, isolated, and encircled with a suture ligature. The trachea was orally intubated and ventilation was adjusted using intermittent measurements of Pace,. The pHa was maintained within the normal range using sodium bicarbonate as necessary. The electrocardiogram and rectal temperature were monitored and temperature was maintained within the normal range with overhead radiant warming lamps. Cerebral temperature was estimated using a needle temperature probe place epicranially under the temporalis muscle. Epicranial temperature was controlled by radiant lamps to remain between 36.0 and 36.5"C.
Each animal was placed into a stereotaxic frame. A 4-mm tip-length microdialysis probe (CMA Microdialysis, Acton, MA) was inserted into the right corpus striatum through a burr hole using predetermined stereotaxic coordinates relative to the bregma Cm.
The techniques of measuring extracellular DA, DOPAC, and HVA using cerebral microdialysis during and after global cerebral ischemia have been previously described in reports from our laboratory (23,24). The microdialysis probes were perfused with artificial cerebrospinal fluid (CSF) at a rate of was not buffered. The perfusate was fed directly into the injector port of the high-performance liquid chromatography (HPLC) system. Samples were analyzed at 15 min intervals. The HPLC system consisted of a Brownlee C-18 Velosep 3 p reverse phase cartridge (3.2 mm internal diameter X 10 cm), a 20-PL injection loop, and a LC-4B electrochemical detector and cell (Bioanalytical Systems, W. Lafayette, IN). The electrochemical detector was set at +0.7 V and an Ag/AgCl electrode was used. The mobile phase consisted of 93 parts 150 mM monochloroacetic acid (pH 3.0) with 0.7 mM EDTA and 2.0 mM sodium octyl sulfate (paired ion reagent) and 7 parts acetonitrile. The HPLC was calibrated using an external standard. Peak heights and retention times of standard solutions were compared with the reference samples and were used to calculate concentrations of constituents. Prior to each experiment, the uniformity and efficiency of each microdialysis probe were tested by immersion in 0.1 N perchloric acid and 40 mg/L diethylenetriamine pentaacetic acid containing 200 pg/pL of DOPAC, HVA, and DA. An in vitro recovery for each probe was calculated for DA, DOPAC, and HVA prior to each experiment using the following equation:
in vitro recovery = recovered concentration standard concentration
The brain concentration was estimated by dividing the effluent dialysate concentration by the in vitro recovery.
The experimental protocol is graphically summarized in Figure 1 . After allowing 60 min for stabilization after probe insertion, baseline effluent was collected (BASE). Animals were randomized to receive either p-nitro-L-arginine-methyl ester (L-NAME) or the vehicle. In order to minimize the systemic effects of L-NAME administration, the drug or vehicle was given through the microdialysis probe as a continuous infusion beginning 30 min prior to ischemia (ISC) and continuing through the experimental period. The concentration of L-NAME used was 0.2 mg/mL (dissolved in artificial CSF), and it was given at the rate of 1.33 FLlmin. This dose of L-NAME was chosen to approximate extracellular L-NAME concentration Change in estimated extracellular concentration of DOPAC and HVA compared to baseline values were calculated for each animal. Differences in physiologic variables, DA, DOPAC, and HVA concentrations were determined by analysis of variance. Post-hoc analysis was performed using Student's t-tests with a Bonferroni's correction to correct for multiple comparisons. Intragroup differences were compared with paired t-tests, while intergroup testing was unpaired. A two-tailed P value less than 0.05 was considered significant.
Results
A summary of the in vitro probe recovery for DA, DOPAC, and HVA is presented in Table 1 . There were eight animals in each group. Physiologic data are summarized in Table 2 . Although the baseline MAP of the control group was lower than the L-NAME group (P < 0.05), there were no other significant differences between the two groups during any study period. Since ' We assumed that L-NAME was distributed throughout total body water, which was estimated as 60% of the rat's weight. If a rat of 0.250 kg is used, (30 mg/kg) . both pressures were within normal limits, it is unlikely that this difference is clinically significant. There were no significant increases in MAP after L-NAME administration and a significant reduction of MAP during ischemia. Estimated extracellular concentrations of DA are presented in Figure 2 . During baseline measurements, DA levels were low in both groups. Although no differences in DA were detected during drug administration, DA was close to the lower limits of detectability. Induction of ischemia resulted in a marked increase in DA in both groups, but there was significant attenuation of the DA increase with L-NAME administration (P < 0.005). The DA concentration remained significantly higher during Rl, R2, and R3 (P < 0.05).
Estimated extracellular concentrations of DOPAC are presented in Figure 3 . No differences in DOPAC were noted between the two groups. There was no significant change in DOPAC with drug or vehicle administration from baseline values. During ischemia, there was a significant decrease in DOPAC compared to baseline in both groups (P < 0.05). During recovery, there was increasing DOPAC in the control group during R3 and R4 (P < 0.05). There were no discernable differences between the pattern of DOPAC extracellular levels between the groups, despite the absence of statistically significant increases in DOPAC levels in the L-NAME group during R3 and R4 (compared to baseline).
The pattern of estimated extracellular concentrations of I-WA mirrored DOPAC (Figure 4 ). There was no significant change in HVA concentration during drug administration. During ischemia and Rl, there was a significant decrease in HVA concentration compared to baseline values during vehicle administration and L-NAME administration (P < 0.05). During R3 and R4, there was a significant increase in I-WA compared to baseline values in the control group (P < 0.05). There were significant intergroup differences during Rl and R4, which revealed a greater change from baseline values with vehicle administration compared with L-NAME administration (P < 0.05).
Discussion
In this study, we examined the effects of NOS inhibition on extracellular DA and DA metabolite concentrations during temporary forebrain ischemia in the rat. During the baseline period, there was no detectable difference in DA concentration between the two groups. Because the baseline levels were at the lower levels of sensitivity, a true difference between these groups cannot be excluded. L-NAME administration significantly attenuated ischemic DA recovery during ischemia and subsequent recovery periods. Rl, R2, R3, and R4 = four consecutive 15-min intervals after reperfusion; L-NAME = No-nitro-L-arginine-methyl ester.
These results support the hypothesis that DA release by dopaminergic neurons during cerebral ischemia is an active phenomenon. Since NOS inhibition reduced DA release, NO may modulate ischemic release of DA from dopaminergic neurons. Most likely, NO is an intermediary in the mechanism of ischemic DA release. The reduction of NO production by L-NAME during ischemia may cause inhibition of DA release through another mechanism. This modulation of ischemic DA release may explain some of the described neurotoxic effects of NO.
DA and other catecholamines may play a direct role in the pathogenesis of neuronal injury. In vitro and in uivo preparations demonstrate that catecholamines are neurotoxic (25,26). Reduction of extraneuronal DA release may attenuate cerebral ischemic injury. Weinberger et al. (10) After bilateral forebrain ischemia, damage to the dopaminergic and other adjacent nerve terminals were substantially attenuated in the DA depleted group compared with the control group. They concluded that DA is intimately related to the evolution of ischemit cerebral injury. These results were supported by Globus et al. (8, 111 . After creation of a unilateral substantia nigra lesion, virtually eliminating dopaminergic input to the striatum, reversible cerebral ischemia was induced. An early postischemic resumption of glucose metabolism without a corresponding increase in CBF was observed in the nonlesioned group. They speculated that DA release resulted in this metabolic uncoupling (Le., mismatch between CBF and In a cat model of focal ischemia, L-NAME administration before and after ischemia resulted in a marked decrease in neuronal injury in the caudate, but not the cortex, compared to control animals (21). We suggest that the differential protection seen in the caudate may be due to the inhibition of DA release observed in the current study. DA neurons are abundant in the caudate and less concentrated in the cortex. If NOS inhibition caused decreased DA release, the greatest area of neuronal protection would be seen in the area with the greatest dopaminergic innervation. Differences between the outcome of these studies may be explained by the differential effects of NO; NO increases CBF and also modulates neurotoxic neurotransmitter release. In models of ischemia where there is a greater ischemic penumbra, the cerebral vasodilation mediated by NO may supplement the CBF and decrease the degree of cerebral injury. In contrast, the increase in the CBF afforded by NO may not be significant in ischemic models with a smaller ischemic penumbra. The neurotoxic effects of NO may be mediated by neurotransmitter release, excitotoxicity, or free radical production.
N-Methyl-d-aspartate increases the in vitro basal DA release from striatial slices (27). This release can be blocked by NOS inhibition and attenuated by addition of hemoglobin (a NO scavenger). Exposure of exogenous cell cultures to NO results in increased DA release. These observations give support that DA release is in response to excitatory neuronal input, and the release of DA is mediated by NO.
Using an in bivo model, Strasser et al. (28) examined the effect of NO inhibition on DA release during ischemia. The investigators infused a NOS inhibitor or vehicle into the gerbil striatum before inducing global ischemia. They observed an attenuation of DA release with NOS inhibition. During ischemia, NOS inhibition did not effect DA release. The differing results from this study compared to the present study may be related to the dose of NOS inhibitor used. The higher dose of NOS inhibitor used by Strasser et al. (28) may have potentiated the decrease in CBF during ischemia, thus increasing extraneuronal DA release. In this model, a NOS inhibitor was injected directly into the neuronal region of study. Although this technique allowed separation of the systemic effects of NO with the local effects of NO, associated beneficial cerebral vasoactive effects of NO during ischemia may not be seen. The increase in CBF afforded by NO may decrease the ischemic penumbra and improve neurologic outcome. In addition, since L-NAME was locally administered, a lower NOS dose was used; and the systemic effects of NOS will be attenuated. The hypertensive effects normally seen with NOS inhibition may increase cerebral perfusion pressure and possibly affect eventual outcome.
In conclusion, an ischemia-induced increase in extracellular DA concentration was attenuated by NOS inhibition at pharmacologic doses. These data support the concept that ischemic DA release may be mediated by NO. These results are consistent with other in vitro and in vim data indicating a modulator effect of NO on DA release. This NO-modulated DA release may contribute to the deleterious neurotoxic effects of NO during ischemia, particularly the selective damage seen in the striatum.
